What is cagrilintide?

Cagrilintide is a long-acting amylin analogue developed through molecular modifications that support prolonged activity. The primary development paper describes a lipidated analogue and the structure–activity work behind its selection. Its amylin-related identity distinguishes it from the GLP-1 pathway represented by semaglutide and liraglutide.

The monotherapy evidence

A multicentre randomized phase 2 trial studied cagrilintide in people with overweight or obesity using placebo and an active comparator. The study found reductions in body weight under the trial conditions. This is direct evidence about the tested intervention and population, rather than an inference drawn solely from its proposed mechanism.

Cagrilintide is not CagriSema

CagriSema combines cagrilintide and semaglutide. A 2025 randomized study evaluated that combination in adults with overweight or obesity and type 2 diabetes. Combination evidence is relevant, but it answers a different question from a trial of cagrilintide alone. The complete result should be attributed to the combination unless the study design supports separating the components’ contributions.

How to compare metabolic trials

Do not rank compounds by taking the largest percentage from unrelated studies. Trial duration, diabetes status, baseline characteristics, background intervention and treatment discontinuation can change the comparison. Also identify the estimand: an analysis that includes outcomes regardless of discontinuation asks a different question from one focused on adherence to assigned treatment.

Efficacy and tolerability belong together

Weight change is only part of a trial report. Adverse events, treatment withdrawal, missing measurements and the burden of remaining on therapy affect the interpretation. A result reported among people who completed treatment should not be presented as the experience of everyone who started. A detailed summary should explain both the outcome and how the analysis handled participants over time.

Scope of this record

This entry describes the cited development and clinical publications, not a live global approval registry. It does not establish that an online product is the same as the trial formulation or that combining separately acquired substances reproduces a studied medicine. For current authorization questions, use the relevant jurisdiction’s product record rather than a trial publication alone.